IP Library › Granted Patent US 12,275,723
Granted Patent B2
US 12,275,723 · App. 18/373,702 · Granted Apr 15, 2025

Compounds and uses thereof

Inventors: Matthew Lucas (Lexington, MA); Bertrand Le Bourdonnec (Northborough, MA); Iwona Wrona (Sharon, MA); Bhaumik Pandya (Bedford, MA); Parcharee Tivitmahaisoon (Boston, MA); Kerem Ozboya (Cambridge, MA); Benjamin Vincent (Cambridge, MA); Daniel Tardiff (Arlington, MA); Jeff Piotrowski (Somerville, MA); Eric Solis (Milford, MA); Robert Scannevin (Hopkinton, MA); Chee-Yeun Chung (Brookline, MA); Rebecca Aron (Cambridge, MA); Kenneth Rhodes (Belmont, MA)
Assignee: JANSSEN PHARMACEUTICA NV
C07D413/14C07D271/07C07D413/04C07D413/10C07D417/04C07D417/14C07D471/04C07D487/04C07D487/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,275,723
App. No.
18/373,702
Granted
Apr 15, 2025
Kind
B2
Abstract

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Claims (18)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, of claim 1 , and a pharmaceutically acceptable excipient.

3. A method of therapeutically treating a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 1 .

4. A method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 1 .

5. The method of claim 4 , wherein the toxicity is α-synuclein-related toxicity.

6. The method of claim 4 , wherein the toxicity is ApoE4-related toxicity.

7. The method of claim 4 , wherein the cell is a mammalian neural cell.

8. A method of therapeutically treating a stearoyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 .

9. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, of claim 9 , and a pharmaceutically acceptable excipient.

11. A method of alleviating the symptoms associated with a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 9 .

12. A method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 9 .

13. The method of claim 12 , wherein the toxicity is α-synuclein-related toxicity.

14. The method of claim 12 , wherein the toxicity is ApoE4-related toxicity.

15. The method of claim 12 , wherein the cell is a mammalian neural cell.

16. A method of alleviating symptoms associated with a stearoyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 9 .

Continuity (4)
Continuation 16758495
Provisional Application 62662424 · Apr 25, 2018
Provisional Application 62576591 · Oct 24, 2017
Related Publication 20240124435A1 · Apr 18, 2024
References Cited (400)
US 4782071A · Butler et al. · 1988 [cited by applicant]
US 5780472A · Cho et al. · 1998 [cited by applicant]
US 6727247B2 · Flohr et al. · 2004 [cited by applicant]
US 7074809B2 · Arora et al. · 2006 [cited by applicant]
US 7132424B2 · Picard · 2006 [cited by applicant]
US 7381749B2 · Malecha et al. · 2008 [cited by applicant]
US 7767677B2 · Kamboj et al. · 2010 [cited by applicant]
US 7790408B1 · Ntambi et al. · 2010 [cited by applicant]
US 8063224B2 · Lachance et al. · 2011 [cited by applicant]
US 8129376B2 · Sundaresan et al. · 2012 [cited by applicant]
US 8207147B2 · Fyfe et al. · 2012 [cited by applicant]
US 8207199B2 · Aoki et al. · 2012 [cited by applicant]
US 8258160B2 · Dales et al. · 2012 [cited by applicant]
US 8314138B2 · Dales et al. · 2012 [cited by applicant]
US 8563539B2 · Baldino et al. · 2013 [cited by applicant]
US 8673917B2 · Zoller et al. · 2014 [cited by applicant]
US 8791136B2 · Goff et al. · 2014 [cited by applicant]
US 8946225B2 · Dupont-Passelaique et al. · 2015 [cited by applicant]
US 9266832B2 · Griffioen et al. · 2016 [cited by applicant]
US 9290465B2 · Derrvberry et al. · 2016 [cited by applicant]
US 9296711B2 · Erickson et al. · 2016 [cited by applicant]
US 10941134B2 · Goff et al. · 2021 [cited by applicant]
US 10973810B2 · Vincent et al. · 2021 [cited by applicant]
US 20020019389A1 · Kim et al. · 2002 [cited by applicant]
US 20040023973A1 · Nagato et al. · 2004 [cited by applicant]
US 20040097483A1 · Zeng et al. · 2004 [cited by applicant]
US 20040127521A1 · Cai et al. · 2004 [cited by applicant]
US 20040146872A1 · Winther et al. · 2004 [cited by applicant]
US 20050119242A1 · Deluca et al. · 2005 [cited by applicant]
US 20050256068A1 · McSwiggen et al. · 2005 [cited by applicant]
US 20060116382A1 · Yao et al. · 2006 [cited by applicant]
US 20060167044A1 · Arnaiz et al. · 2006 [cited by applicant]
US 20060270686A1 · Kelly et al. · 2006 [cited by applicant]
US 20070087363A1 · Bartel et al. · 2007 [cited by applicant]
US 20080015230A1 · Kamboj et al. · 2008 [cited by applicant]
US 20080021028A1 · Swinnen et al. · 2008 [cited by applicant]
US 20080132542A1 · Lachance et al. · 2008 [cited by applicant]
US 20080207587A1 · Kamboj et al. · 2008 [cited by applicant]
US 20080249100A1 · Chisholm et al. · 2008 [cited by applicant]
US 20080255130A1 · Koltun et al. · 2008 [cited by applicant]
US 20080255161A1 · Koltun et al. · 2008 [cited by applicant]
US 20080280891A1 · Kelly et al. · 2008 [cited by applicant]
US 20090098105A1 · Hopf et al. · 2009 [cited by applicant]
US 20090118296A1 · Black et al. · 2009 [cited by applicant]
US 20090149466A1 · Gillespie et al. · 2009 [cited by applicant]
US 20090163545A1 · Goldfarb · 2009 [cited by applicant]
US 20090170822A1 · DeLuca et al. · 2009 [cited by applicant]
US 20090170828A1 · Isabel et al. · 2009 [cited by applicant]
US 20090221597A1 · Hadida et al. · 2009 [cited by applicant]
US 20090239810A1 · Sundaresan et al. · 2009 [cited by applicant]
US 20090246137A1 · Hadida Ruah et al. · 2009 [cited by applicant]
US 20090253693A1 · Koltun et al. · 2009 [cited by applicant]
US 20090253738A1 · Koltun et al. · 2009 [cited by applicant]
US 20090325956A1 · Taniguchi et al. · 2009 [cited by applicant]
US 20100022486A1 · Bouillot et al. · 2010 [cited by applicant]
US 20100029722A1 · Dales et al. · 2010 [cited by applicant]
US 20100041696A1 · Daugan et al. · 2010 [cited by applicant]
US 20100160323A1 · Bischoff et al. · 2010 [cited by applicant]
US 20100210649A1 · Djaballah et al. · 2010 [cited by applicant]
US 20120010186A1 · Lachance et al. · 2012 [cited by applicant]
US 20120178678A1 · Dupont-Passelaigue et al. · 2012 [cited by applicant]
US 20120196844A1 · Alper et al. · 2012 [cited by applicant]
US 20120252850A1 · Milne et al. · 2012 [cited by applicant]
US 20120316182A1 · Whitten et al. · 2012 [cited by applicant]
US 20130011361A1 · Dales et al. · 2013 [cited by applicant]
US 20130225529A1 · Rigas · 2013 [cited by applicant]
US 20130317020A1 · Ruah et al. · 2013 [cited by applicant]
US 20140364393A1 · Yang et al. · 2014 [cited by applicant]
US 20150051206A1 · Loren et al. · 2015 [cited by applicant]
US 20150087673A1 · Hitoshi et al. · 2015 [cited by applicant]
US 20150246893A1 · Devaraj et al. · 2015 [cited by applicant]
US 20150252032A1 · Bolli et al. · 2015 [cited by applicant]
US 20160223559A1 · Devaraj et al. · 2016 [cited by applicant]
US 20160251336A1 · Yang et al. · 2016 [cited by applicant]
US 20160332989A1 · Wu et al. · 2016 [cited by applicant]
US 20170174699A1 · Hadari et al. · 2017 [cited by applicant]
US 20180015068A1 · Inoue et al. · 2018 [cited by applicant]
US 20180193325A1 · Vincent et al. · 2018 [cited by applicant]
US 20190302121A1 · Copland, III et al. · 2019 [cited by applicant]
US 20190330198A1 · Wrona et al. · 2019 [cited by applicant]
US 20200010462A1 · Lucas et al. · 2020 [cited by applicant]
US 20200262828A1 · Lucas et al. · 2020 [cited by applicant]
US 20210139471A1 · Wrona et al. · 2021 [cited by applicant]
US 20220040167A1 · Vincent et al. · 2022 [cited by applicant]
CN 1177352A · 1998 [cited by applicant]
CN 1630650A · 2005 [cited by applicant]
CN 101083994A · 2007 [cited by applicant]
CN 101128435A · 2008 [cited by applicant]
CN 101137363A · 2008 [cited by applicant]
CN 101589039A · 2009 [cited by applicant]
CN 101641347A · 2010 [cited by applicant]
CN 101835776A · 2010 [cited by applicant]
CN 103221408A · 2013 [cited by applicant]
CN 103328482A · 2013 [cited by applicant]
CN 103619825A · 2014 [cited by applicant]
CN 103748087A · 2014 [cited by applicant]
CN 104163794 · 2014 [cited by applicant]
EP 1193255 · 2002 [cited by applicant]
EP 1737451A2 · 2007 [cited by applicant]
EP 2455080A1 · 2012 [cited by applicant]
EP 2455081A1 · 2012 [cited by applicant]
EP 2980077A1 · 2016 [cited by applicant]
EP 2990400 · 2016 [cited by applicant]
EP 3284738A1 · 2018 [cited by applicant]
EP 3381908A1 · 2018 [cited by applicant]
JP H11501021A · 1999 [cited by applicant]
JP 2005213233 · 2005 [cited by applicant]
JP 2008513514A · 2008 [cited by applicant]
JP 2008525478A · 2008 [cited by applicant]
JP 2008526796A · 2008 [cited by applicant]
JP 2008545760A · 2008 [cited by applicant]
JP 2009019013 · 2009 [cited by applicant]
JP 2009501733A · 2009 [cited by applicant]
JP 201043052 · 2010 [cited by applicant]
JP 2010506859A · 2010 [cited by applicant]
JP 2010510993A · 2010 [cited by applicant]
JP 2010513400 · 2010 [cited by applicant]
JP 2010516714A · 2010 [cited by applicant]
JP 2010535847A · 2010 [cited by applicant]
JP 2011529102A · 2011 [cited by applicant]
JP 2012518603A · 2012 [cited by applicant]
JP 2013537180A · 2013 [cited by applicant]
JP 2014501274A · 2014 [cited by applicant]
JP 2014509600A · 2014 [cited by applicant]
JP 2014510708A · 2014 [cited by applicant]
JP 2014513071A · 2014 [cited by applicant]
JP 2014518240A · 2014 [cited by applicant]
KR 20150014719 · 2015 [cited by applicant]
KR 20150015305 · 2015 [cited by applicant]
KR 20160020616 · 2016 [cited by applicant]
WO WO9626937A1 · 1996 [cited by applicant]
WO WO9963979 · 1999 [cited by applicant]
WO WO0020414A · 2000 [cited by applicant]
WO WO0114339 · 2001 [cited by applicant]
WO WO0105769 · 2001 [cited by applicant]
WO WO02066470 · 2002 [cited by applicant]
WO WO03070885 · 2003 [cited by applicant]
WO WO03084948A1 · 2003 [cited by applicant]
WO WO2004014892 · 2004 [cited by applicant]
WO WO2005011654 · 2005 [cited by applicant]
WO WO2005011655 · 2005 [cited by applicant]
WO WO2005011656 · 2005 [cited by applicant]
WO WO2005011657 · 2005 [cited by applicant]
WO WO2005014607 · 2005 [cited by applicant]
WO WO2005023833 · 2005 [cited by applicant]
WO WO2006012325 · 2006 [cited by applicant]
WO WO2006014168 · 2006 [cited by applicant]
WO WO2006015621 · 2006 [cited by applicant]
WO WO2006022442 · 2006 [cited by applicant]
WO WO2006034279 · 2006 [cited by applicant]
WO WO2006034312 · 2006 [cited by applicant]
WO WO2006034315 · 2006 [cited by applicant]
WO WO2006034338 · 2006 [cited by applicant]
WO WO2006034341 · 2006 [cited by applicant]
WO WO2006034440A2 · 2006 [cited by applicant]
WO WO2006034441 · 2006 [cited by applicant]
WO WO2006034446 · 2006 [cited by applicant]
WO WO2006057902 · 2006 [cited by applicant]
WO WO2006067531 · 2006 [cited by applicant]
WO WO2006071730A1 · 2006 [cited by applicant]
WO WO2006072436A1 · 2006 [cited by applicant]
WO WO2006074025 · 2006 [cited by applicant]
WO WO2006086445 · 2006 [cited by applicant]
WO WO2006086447 · 2006 [cited by applicant]
WO WO2006116713 · 2006 [cited by applicant]
WO WO2006125179 · 2006 [cited by applicant]
WO WO2006125181 · 2006 [cited by applicant]
WO WO2006125194 · 2006 [cited by applicant]
WO WO2006130986A1 · 2006 [cited by applicant]
WO WO2007009236A1 · 2007 [cited by applicant]
WO WO2007044085 · 2007 [cited by applicant]
WO WO2007046868 · 2007 [cited by applicant]
WO WO2007056846 · 2007 [cited by applicant]
WO WO2007076055A2 · 2007 [cited by applicant]
WO WO2007079180 · 2007 [cited by applicant]
WO WO2007120702A2 · 2007 [cited by applicant]
WO WO2007130075 · 2007 [cited by applicant]
WO WO2007134457 · 2007 [cited by applicant]
WO WO2007136746 · 2007 [cited by applicant]
WO WO2007143597 · 2007 [cited by applicant]
WO WO2007143823 · 2007 [cited by applicant]
WO WO2007143824 · 2007 [cited by applicant]
WO WO2008008852A2 · 2008 [cited by applicant]
WO WO2008008854A2 · 2008 [cited by applicant]
WO WO2008003753 · 2008 [cited by applicant]
WO WO2008008059 · 2008 [cited by applicant]
WO WO2008017161 · 2008 [cited by applicant]
WO WO2008023720A1 · 2008 [cited by applicant]
WO WO2008024139 · 2008 [cited by applicant]
WO WO2008024390 · 2008 [cited by applicant]
WO WO2008029266A1 · 2008 [cited by applicant]
WO WO2008036715 · 2008 [cited by applicant]
WO WO2008043087 · 2008 [cited by applicant]
WO WO2008044767 · 2008 [cited by applicant]
WO WO2008046226A1 · 2008 [cited by applicant]
WO WO2008056687 · 2008 [cited by applicant]
WO WO2008057280 · 2008 [cited by applicant]
WO WO2008061795 · 2008 [cited by applicant]
WO WO2008062276 · 2008 [cited by applicant]
WO WO2008076356A1 · 2008 [cited by applicant]
WO WO2008064474A1 · 2008 [cited by applicant]
WO WO2008074824 · 2008 [cited by applicant]
WO WO2008074832 · 2008 [cited by applicant]
WO WO2008074833 · 2008 [cited by applicant]
WO WO2008074834 · 2008 [cited by applicant]
WO WO2008074835 · 2008 [cited by applicant]
WO WO2008089580A1 · 2008 [cited by applicant]
WO WO2008096746 · 2008 [cited by applicant]
WO WO2008104524 · 2008 [cited by applicant]
WO WO2008116898 · 2008 [cited by applicant]
WO WO2008120744 · 2008 [cited by applicant]
WO WO2008120759 · 2008 [cited by applicant]
WO WO2008123469 · 2008 [cited by applicant]
WO WO2008127349 · 2008 [cited by applicant]
WO WO2008128335 · 2008 [cited by applicant]
WO WO2008139845 · 2008 [cited by applicant]
WO WO2008141455 · 2008 [cited by applicant]
WO WO2008157844 · 2008 [cited by applicant]
WO WO2009010560 · 2009 [cited by applicant]
WO WO2009012573 · 2009 [cited by applicant]
WO WO2009016216 · 2009 [cited by applicant]
WO WO2009019566 · 2009 [cited by applicant]
WO WO2009021990A1 · 2009 [cited by applicant]
WO WO2009037542 · 2009 [cited by applicant]
WO WO2009060053A1 · 2009 [cited by applicant]
WO WO2009056556 · 2009 [cited by applicant]
WO WO2009060054 · 2009 [cited by applicant]
WO WO2009070533 · 2009 [cited by applicant]
WO WO2009073973 · 2009 [cited by applicant]
WO WO2009103739 · 2009 [cited by applicant]
WO WO2009106991 · 2009 [cited by applicant]
WO WO2009117659 · 2009 [cited by applicant]
WO WO2009123896 · 2009 [cited by applicant]
WO WO2009124259 · 2009 [cited by applicant]
WO WO2009129625 · 2009 [cited by applicant]
WO WO2009150196 · 2009 [cited by applicant]
WO WO2009156484 · 2009 [cited by applicant]
WO WO2010006962 · 2010 [cited by applicant]
WO WO2010007482 · 2010 [cited by applicant]
WO WO2010007966A1 · 2010 [cited by applicant]
WO WO2010022055A2 · 2010 [cited by applicant]
WO WO2010013037A1 · 2010 [cited by applicant]
WO WO2010025553 · 2010 [cited by applicant]
WO WO2010039186A2 · 2010 [cited by applicant]
WO WO2010035052 · 2010 [cited by applicant]
WO WO2010037225 · 2010 [cited by applicant]
WO WO2010043052 · 2010 [cited by applicant]
WO WO2010045371 · 2010 [cited by applicant]
WO WO2010045374 · 2010 [cited by applicant]
WO WO2010056230 · 2010 [cited by applicant]
WO WO2010057833 · 2010 [cited by applicant]
WO WO2010060996 · 2010 [cited by applicant]
WO WO2010094120 · 2010 [cited by applicant]
WO WO2010094126A · 2010 [cited by applicant]
WO WO2010108268A1 · 2010 [cited by applicant]
WO WO2010101964 · 2010 [cited by applicant]
WO WO2010112520 · 2010 [cited by applicant]
WO WO2011011506 · 2011 [cited by applicant]
WO WO2011011508 · 2011 [cited by applicant]
WO WO2011011872 · 2011 [cited by applicant]
WO WO2011015629 · 2011 [cited by applicant]
WO WO2011025690A · 2011 [cited by applicant]
WO WO2011030312 · 2011 [cited by applicant]
WO WO2011039358 · 2011 [cited by applicant]
WO WO2011047481 · 2011 [cited by applicant]
WO WO2011109059 · 2011 [cited by applicant]
WO WO2011123681 · 2011 [cited by applicant]
WO WO2011131593 · 2011 [cited by applicant]
WO WO2011157793 · 2011 [cited by applicant]
WO WO2012009134 · 2012 [cited by applicant]
WO WO2012016217 · 2012 [cited by applicant]
WO WO2012035023A1 · 2012 [cited by applicant]
WO WO2012046681 · 2012 [cited by applicant]
WO WO2012066077A1 · 2012 [cited by applicant]
WO WO2012080729 · 2012 [cited by applicant]
WO WO2012082817 · 2012 [cited by applicant]
WO WO2012093809A2 · 2012 [cited by applicant]
WO WO2012123449A1 · 2012 [cited by applicant]
WO WO2012136492A1 · 2012 [cited by applicant]
WO WO2012169649A1 · 2012 [cited by applicant]
WO WO2013004642A1 · 2013 [cited by applicant]
WO WO2013026587A1 · 2013 [cited by applicant]
WO WO2013046136A1 · 2013 [cited by applicant]
WO WO2013056148A2 · 2013 [cited by applicant]
WO WO2013070660A1 · 2013 [cited by applicant]
WO WO2013085954 · 2013 [cited by applicant]
WO WO2013085957 · 2013 [cited by applicant]
WO WO2013098373A1 · 2013 [cited by applicant]
WO WO2013134546 · 2013 [cited by applicant]
WO WO2013160811 · 2013 [cited by applicant]
WO WO2013170072 · 2013 [cited by applicant]
WO WO2014003153 · 2014 [cited by applicant]
WO WO2014031928 · 2014 [cited by applicant]
WO WO2014092104A1 · 2014 [cited by applicant]
WO WO2014116386 · 2014 [cited by applicant]
WO WO2015048547 · 2015 [cited by applicant]
WO WO2015101293A1 · 2015 [cited by applicant]
WO WO2015113920A1 · 2015 [cited by applicant]
WO WO2015132610 · 2015 [cited by applicant]
WO WO2015137385 · 2015 [cited by applicant]
WO WO2015140130A1 · 2015 [cited by applicant]
WO WO2016022626 · 2016 [cited by applicant]
WO WO2016022955 · 2016 [cited by applicant]
WO WO2016040794 · 2016 [cited by applicant]
WO WO2016049586A2 · 2016 [cited by applicant]
WO WO2016098005A1 · 2016 [cited by applicant]
WO WO2016107603 · 2016 [cited by applicant]
WO WO2017066705 · 2017 [cited by applicant]
WO WO2017112777A1 · 2017 [cited by applicant]
WO WO2017093263 · 2017 [cited by applicant]
WO WO2017212425 · 2017 [cited by applicant]
WO WO2018026663A1 · 2018 [cited by applicant]
WO WO2018081167A1 · 2018 [cited by applicant]
WO WO2018112077 · 2018 [cited by applicant]
WO WO2018129403 · 2018 [cited by applicant]
WO WO2018160717 · 2018 [cited by applicant]
WO WO2018161033 · 2018 [cited by applicant]
WO WO2018195450A1 · 2018 [cited by applicant]
WO WO2019018795 · 2019 [cited by applicant]
WO WO2019084157 · 2019 [cited by applicant]
WO WO2019123375 · 2019 [cited by applicant]
WO WO2019123378 · 2019 [cited by applicant]
WO WO2019140188 · 2019 [cited by applicant]
WO WO2019173394 · 2019 [cited by applicant]
WO WO2019183587 · 2019 [cited by applicant]
WO WO2019209948 · 2019 [cited by applicant]
WO WO2019209962 · 2019 [cited by applicant]
WO WO2020023657 · 2020 [cited by applicant]
WO WO2020132378 · 2020 [cited by applicant]
WO WO2020154571 · 2020 [cited by applicant]
WO WO2020198026 · 2020 [cited by applicant]
WO WO2021092240 · 2021 [cited by applicant]
WO WO2021092262 · 2021 [cited by applicant]
WO WO2021097240 · 2021 [cited by applicant]
WO WO2021139595 · 2021 [cited by applicant]
WO WO2021154571 · 2021 [cited by applicant]
Huestis et al., “The Vinyl Moiety as a Handle for regiocontrol in the Preparation of Unsymmetrical 2,3-Aliphatic-Substituted Indoles and Pyrroles,” Anqew Chem Int Ed Enql. 50(6):1338-41 (2011). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/57339, mailed Apr. 1, 2019 (18 pages). [cited by applicant]
Jarvis et al., “A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat,” Proc Natl Acad Sci U.S.A. 104(20):8520-5 (2007). [cited by applicant]
PubChem Compound Summary for CID 127868748, dated Jun. 18, 2017 (9 pages). [cited by applicant]
PubChem Compound Summary for CID 7059272, dated Jul. 29, 2006 (12 paqes). [cited by applicant]
PubChem Compound Summary for CID 126485826, dated Apr. 22, 2017 (6 pages). [cited by applicant]
PubChem Compound Summary for CID 53003909, dated Jun. 21, 2011 (7 pages). [cited by applicant]
PubChem Compound Summary for CID 56980069, dated Jun. 13, 2012 (11 pages). [cited by applicant]
PubChem Compound Summary for CID 127012056, dated Jun. 2, 2017 (12 pages). [cited by applicant]
PubChem Compound Summary for CID 15985883, “5-[5-[4-[(4-Chlorophenyl)methyl]piperidin-1-yl]-5-oxopentyl]-1H-pyridin-2-one,” created Mar. 27, 2007, retrieved Mar. 25, 2020 (7 pages). [cited by applicant]
“List of neurological conditions and disorders,” <https://en.wikipedia.org/wiki/List_of_neurological_conditions_and_disorders>. [cited by applicant]
Astarita et al., “Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease,” PLoS One. 6(10):e24777 (2011) (9 pages). [cited by applicant]
Bähler et al., “Heterologous modules for efficient and versatile PCR-based gene targeting in Schizosaccharomyces pombe.” Yeast. 14(10):943-51 (1998). [cited by applicant]
Berge et al., “Pharmaceutical salts,” J Pharm Sci. 66(1):1-19 (1977). [cited by applicant]
Berlin et al., 16(4) Bioorg. & Med. Chem. Letts., pp. 989-994 (2006). [cited by applicant]
Black et al., “Advances and limitations in the evaluation of analgesic combination therapy,” Neurology. 65(12 Suppl 4):S3-6 (2005) (14 pages). [cited by applicant]
Chung et al., “Identification and rescue of alpha-synuclein toxicity in Parkinson patient-drived neurons,” available in PMC Nov. 22, 2014, published in final edited form as: Science. 342(6161):983-7 (2013) (12 pages). [cited by applicant]
Cingolani et al., “A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of [cited by applicant]
Cooper et al., “Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models,” available in PMC Sep. 19, 2007, published in final edited form as: Science. 313(5785):324-8 (2006) (12 pages). [cited by applicant]
Crews et al., “Role of Svnucleins in Alzheimer's Disease,” Neurotox Res. 16(3):306-317 (2009). [cited by applicant]
Dai et al., “SCD1 Confes Temozolomide Resistance to Human Glioma Cells via Akt/GSK3β/β-Catenin Signaling Axis,” Frontiers in Pharmacology, vol. 8, Art. 960 (2018). [cited by applicant]
Debenham et al., “Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase1-3 (HIF PHD1-3)… [cited by applicant]
Dillon et al., “Development of a novel LC(MS method to quantitate cellular stearoyl-CoA desaturase activity,” Anal Chim Acta. 627(1):99-104 (2008). [cited by applicant]
Fatutta et al., “Comportamento di alcune idrazidi di fronte a composti y-dicarbonilici. (*)”,Gazzetta Chimica Italiana, Societa Chimica Italiana, IT, vol. 90, Jan. 1, 1960 (Jan. 1, 1960), pp. 1645-1657. [cited by applicant]
Friedrich et al., “Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicitv,” Proc Natl Acad Sci U.S.A. 107(5):1942-7 (2010). [cited by applicant]
Gallagher et al., “Ceapins are a new class of unfolded protein response inhibitors, selectively targeting the ATF6α branch,” eLife 2016; 5: e11878, 1-33 (2016). [cited by applicant]
Garrison et al., “Haplotype-based variant detection from short-read sequencing,” <https:((arxiv.org/pdf/1207.3907.pdf> (2012) (9 pages). [cited by applicant]
Gietz, “Yeast transformation by the LiAc/SS carrier DNA/PEG method,” Methods Mol Biol. 1205:1-12 (2014). [cited by applicant]
Goedert, M., “Parkinson's disease and other alpha-synucleinopathies,” Clin Chem Lab Med. 39(4):308-12 (2001) (Abstract only). [cited by applicant]
Hamilton et al., “Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease,” Cell Stem Cell. 17(4):397-411 (2015) (16 pages). [cited by applicant]
Kamboh et al., “A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease” Neurosci Lett. 263(2-3):129-32 (1999). [cited by applicant]
Larson et al., “Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology,” Available in PMC Jan. 25, 2013, published in final edited form as: J Neurosci. 32(30):10253-66 (2012) (28 pages). [cited by applicant]
Li et al., “Fast and accurate long-read alignment with Burrows-Wheeler transform,” Bioinformatics. 26(5):589-95 (2010). [cited by applicant]
Li et al., “Fast and accurate short read alignment with Burrows-Wheeler transform,” Bioinformatics. 25(14):1754-60 (2009). [cited by applicant]
Li et al., “The sequence alignment/map format and SAMtools,” Bioinformatics. 25(16):2078-9 (2009). [cited by applicant]
Longtine et al., “Additional modules for versatile and economical PCR-based gene deletion and modification in [cited by applicant]
Maya S. Salnikova, “Rational Development of Protein Formulations in Solid and Solution States,” 2007. [cited by applicant]
Mikolaenko et al., “Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA),” J Neuropathol Exp Neurol. 64(2):156-62 (2005}. [cited by applicant]
Miyazaki et al., “The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1,” J Biol Chem. 275(39):30132-8 (2000). [cited by applicant]
Oatman et al. “Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer” Science Advances. Feb. 10, 2021 vol 7, p. 1-19. [cited by applicant]
Pankratz et al., “Presence of an APOE4 Allele Results in Significantly Earlier Onset of Parkinson's Disease and a Higher Risk With Dementia,” Mov Disord. 21(1):45-49 (2006). [cited by applicant]
Piotrowski et al., “Plant-derived antifungal agent poacic acid targets beta-1,3-glucan,” Proc Natl Acad Sci U S A. 112(12):E1490-7 (2015). [cited by applicant]
Ponomarenko et al., “The Size of the Human Proteome: The Width and Depth,” Int J Anal Chem. 2016:7426849 (2016) (6 pages). [cited by applicant]
Shanklin et al., “Stearoyl-acyl-carrier-protein desaturase from higher plants is structurally unrelated to the animal and fungal homologs,” Proc Natl Acad Sci US A. 88(6):2510-4 (1991). [cited by applicant]
Simon et al., “Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.” Mol Cell Proteomics. … [cited by applicant]
Sinner et al., “StearoylCoA Desaturase-5: A novel regulator of neuronal cell proliferation and differentiation” PLoS One. 7(6):e39787 (2012) (12 pages). [cited by applicant]
Skedelj et al., “ATP-Binding Site of Bacterial Enzymes as a Target for Antibacterial Drug Design”, Journal of Medicinal Chemistry, vol. 54, No. 4, Jan. 14, 2011 (Jan. 14, 2011), pp. 915-929. [cited by applicant]
Soulard et al., “Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry,” Anal Chim Acta. 627(1):105-11 (2008). [cited by applicant]
Su et al., “Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models,” Dis Model Mech. 3(3-4):194-208 (2010). [cited by applicant]
Suzuki et al., “Knocking out multi-gene redundancies via cycles of sexual assortment and fluorescence selection,” available in PMC Aug. 1, 2011, published in final edited form as: Nat Methods. 8(2):159-64 (Feb. 2011) (1… [cited by applicant]
Tafesse et al., “Disruption of Sphingolipid Biosynthesis Blocks Phagocytosis of Candida albicans,” PLoS Pathog. 11(10):e1005188 (2015) (27 pages). [cited by applicant]
Terry-Kantor et al., “Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor,” Int. J. Mol. Sci., 21, 5193, 1-16 (Jul. 22. 2020). [cited by applicant]
Tesfay et al., “Steroyl-CoA Desaturase (SCD1) protects ovarian cancer cells from ferroptotic cell death,” Cancer Res. 79(20): 5355-5366 (Oct. 15, 2019). [cited by applicant]
Tindale et al., “Rare and common variants in the Apolipoprotein E gene in healthy oldest old,” Neurobiol Aging. 35(3):727.e1-3 (2014) (3 pages). [cited by applicant]
Verghese et al.,“Roles of Apolipoprotein E in Alzheimer's disease and other neurological disorders,” Lancet Neurol. 10(3):241-252 (2011). [cited by applicant]
Wang et al., “Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates,” Biochem Biophys Res Commun. 332(3):735-42 (2005). [cited by applicant]
Zhang et al., “Revisiting the Medical Management of Parkinson's Disease: Levodopa Versus Dopamine Agonist,” Curr Neuropharmacol. 14(4):356-363 (2016). [cited by applicant]
Zhang et al., “Opportunities and Challenges in Develping Stearoyl-Coenzyme A Desaturase-1 Inhibitors as Novel Therapeutics for Human Disease,” J. Med. Chem., 57, 5039-5056 (2014). [cited by applicant]
Zhou, Youping, Zhong, et al. Inhibition of stearoyl-coenzyme A desaturase 1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy. Aging, 12(8):7350-7362 (Apr. 23, 2020). [cited by applicant]
NCBI, Gene ID: 79966, “SCD5 stearoyl-CoA desaturase 5 [ [cited by applicant]
PubChem CID 91412014, Create Date: Mar. 17, 2015 (Mar. 17, 2015), p. 2, Fig. [cited by applicant]
STN RN 1358463-36-1 (entered STN Feb. 29, 2012). [cited by applicant]
STN RN1266245-83-3 (entered STN Mar. 3, 2011). [cited by applicant]
Madia Valentina Noemi et al., “Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity”, Journal of Medicinal Chemistry, vol. 61, No. 15, Jul. 16, 2018 (Jul. 16, 2018), pp. 6918-6936, XP093025853, US. [cited by applicant]